CARLSBAD, Calif. & SHANGHAI, China--(BUSINESS WIRE)--Oct 31, 2005 - Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it has entered into a collaborative research agreement with the National Center for Drug Screening (NCDS), a public technology organization in Shanghai and the only national center specialized in screening for new drugs in China. The NCDS is home to thousands of unique synthetic compounds and extracts from natural products that are at the heart of traditional Chinese medicine. Financial terms of the collaboration were not disclosed.

The collaborative research agreement calls for the cooperative use of proprietary Invitrogen drug discovery technologies, such as GeneBLAzer(TM) and Polar Screen(TM), as well as development of new assays and techniques specific to the collaboration. These technologies and assays will focus on the high-throughput screening of unique compound libraries against nuclear receptors at the organization.